Renal tubular acidosis primary prevention

Jump to navigation Jump to search

Renal tubular acidosis Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Renal tubular acidosis from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X-ray

Echocardiography and Ultrasound

CT scan

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Renal tubular acidosis primary prevention On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Renal tubular acidosis primary prevention

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Renal tubular acidosis primary prevention

CDC on Renal tubular acidosis primary prevention

Renal tubular acidosis primary prevention in the news

Blogs on Renal tubular acidosis primary prevention

Directions to Hospitals Treating Psoriasis

Risk calculators and risk factors for Renal tubular acidosis primary prevention

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] ;Associate Editor(s)-in-Chief: Aditya Ganti M.B.B.S. [2]

Overview

There are no effective primary preventive measures for renal tubular acidosis. However, preventive approaches can be helpful in the case of Fanconi syndrome secondary to toxin exposure which includes regulation of the use of medications responsible in high-risk groups with caution.

Primary Prevention

There are no effective primary preventive measures for renal tubular acidosis. However, preventive approaches can be helpful in the case of Fanconi syndrome secondary to toxin exposure which includes:

  • Regulation of the use of both lead and cadmium exposure in high-risk groups with caution.
  • Changes in tetracycline manufacture.
  • Use of cisplatin at lower dose levels.
  • Avoidance of the offending agents in patients with hereditary sensitivity to particular carbohydrates.

References